David Augustine Lynch MBBCh, Presenter: Research support, Siemens AG Scientific Advisor, PAREXEL International Corporation Consultant, Boehringer Ingelheim GmbH Consultant, InterMune, Inc Consultant, Gilead Sciences, Inc Consultant, F. Hoffmann-La Roche Ltd Consultant, Veracyte, Inc Research support, Johnson & Johnson Research support, AstraZeneca PLC

1) Describe the methodology and limitations of non-invasive imaging in quantifying lung structure. 2) Describe the opportunities for non-invasive imaging in understanding the structure of the lung, and how that relates to phenotyping subjects for clinical trials and longitudinal studies. 3) Understand the clinical relevance of quantitative imaging of COPD. 4) Learn how to interpret quantitative CT results in the lung.

COPD is characterized on CT by emphysema, bronchial wall thickening, and small airway abnormalities. These morphologic findings may be quantified and grouped into phenotypes, with different clinical presentations and prognosis.  Clinicians are increasingly using these quantitative imaging techniques to study COPD.  This course will provide information on the results of large-scale clinical trials ongoing in COPD. The limitations and sources of variation of current quantitative imaging methods will be discussed. Relationships between quantitative CT measures, genetic markers, and clinical abnormalities will be stressed. 

Lynch, D, Quantitation in the Assessment of COPD.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/12020961.html